NEW CEO AND $25M FUNDRAISED BY CAN TOO FOUNDATION
April 2022 is a big month for the *Can Too Foundation, with it today announcing the appointment of **Paul Rose as its new CEO and passing $25 million fundraised for cancer research and prevention.
Can Too Foundation is a significant Australian independent health promotion charity, committed to funding cancer research and prevention since 2005.
“I am pleased to announce that after an extensive recruitment process, Paul Rose has been appointed CEO of the Can Too Foundation,” Can Too Chair, Simon Buckingham, said.
Mr Rose is an exceptional leader with 30 years top tier international corporate experience. His most recent position prior to joining Can Too was as Global President, of Delayed Close Markets for Pfizer Consumer Healthcare. He has been a previous CEO/ General Manager of consumer healthcare for both Pfizer and GlaxoSmithKline (GSK) in both Australia and New Zealand.
“Not only does Paul have an outstanding corporate track record, but I believe he embodies the warm, inclusive and supportive culture of Can Too, with clear capability to ‘inspire, engage, support, and empower’ the organisation and everyone that is involved with it.
“Paul has been brought on board with a mandate to significantly grow Can Too’s geographic and demographic reach and social impact – we believe Can Too’s vibrant community and expertise puts it in a great position to improve people’s mental and physical health during the COVID-19 pandemic and beyond.”
Newly appointed Can Too Foundation CEO, Paul Rose, said, “Joining the Can Too Foundation and combining my passion for mental and physical health through wellness empowerment, whilst raising vitally needed funds to support the research, prevention, care and control of cancer, is both an honour and a privilege.”
Mr Rose is also a cancer survivor having been diagnosed with three separate cancers in 2020. Early detection, surgery and radiation treatment led to each cancer being non-invasive and Paul has made a full recovery.
Reaching the fundraising milestone of $25 million for cancer research and prevention since inception in 2005 is a significant milestone for the Can Too Foundation.
“Reaching $25 million in fundraising is a credit to the collective efforts of the 17,000 plus participants in our coached programs, our amazing staff, supporters and dedicated board members – onward to the next $25 million!,” Dr Buckingham said.
The Can Too Foundation acknowledges big challenges ahead, such as disruption from COVID-19 and climate change, but believes through leadership and empowerment they can continue to improve lives and raise significant funds to prevent cancer and fund cancer research.
“In welcoming Paul Rose as the new Can Too CEO, I would like to acknowledge the tremendous efforts of our past CEOs, as well as the amazing agility and hard work of our staff and Interim CEO, Gary Trenaman, who will continue to play a significant and expanded leadership role in the organisation,” Dr Buckingham said.
